# A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

Study · id `cardio:ct-nct07613294` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07613294](<https://clinicaltrials.gov/study/NCT07613294>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07613294

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 252 participants.

## Technical summary

Registry record NCT07613294. Randomized; double masking; primary purpose treatment. Start 2026-06-01 (actual); primary completion 2029-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 252 participants (planned count; ClinicalTrials.gov record NCT07613294, source copy `cardio:ctgov-nct07613294-2026-11-04`, retrieved 2026-11-18)
- Started: 2026-06-01 (actual) (ClinicalTrials.gov record NCT07613294, source copy `cardio:ctgov-nct07613294-2026-11-04`, retrieved 2026-11-18)
- Primary completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT07613294, source copy `cardio:ctgov-nct07613294-2026-11-04`, retrieved 2026-11-18)
- Completion: 2029-12 (anticipated) (ClinicalTrials.gov record NCT07613294, source copy `cardio:ctgov-nct07613294-2026-11-04`, retrieved 2026-11-18)
- Countries: United States; Australia; Czechia; Hungary; Netherlands; Spain; United Kingdom (ClinicalTrials.gov record NCT07613294, source copy `cardio:ctgov-nct07613294-2026-11-04`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07613294-2026-11-04`, retrieved 2026-11-18)

## The registry's words

- Brief title: A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
- Acronym: ACCLAIM-CTA
- Condition: Atherosclerosis
- Condition: Cardiovascular Diseases
- Condition: Lipoprotein(a)
- Intervention (Drug): Lepodisiran
- Intervention (Drug): Placebo
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 750650533fbb587011f59c3879080a7af1b11e86737ff76e99779196a18f5330
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
